A US Senate vote on so-called “surprise” billing and balanced billing legislation will have to wait until after Labor Day in September to allow for consideration of more senators’ input, bill sponsors Lamar Alexander and Patty Murray announced on 24 July.
Consideration of proposed balanced billing legislation in the Senate will continue into the fall, following a 24 July statement by sponsors Sens. Lamar Alexander, R-TN, and Patty Murray, D-WA, that the chamber will not vote on the measure until September at the earliest.
S. 1895, The Lower Health Care Costs Act, would reduce what Americans have to pay for portions of the...
Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.
At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.
Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.
NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.
The US FDA has cleared NeuroOne's OneRF trigeminal nerve ablation system for the treatment of trigeminal neuralgia. This minimally invasive method utilizes radio frequency energy to alleviate pain, offering an alternative to traditional medications and surgeries. A fall commercial launch is planned.
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.
